Quick Facts

• Primary Use: Management of symptoms related to motion sickness.
• Therapeutic Focus: Helps manage or prevent nausea, vomiting, and dizziness associated with travel.

Touristil is a prescription and over-the-counter medication intended for the prevention and management of symptoms associated with motion sickness. The medication is commonly used to help manage the feelings of discomfort, including nausea, vomiting, and dizziness, that may arise during various forms of travel, such as by car, boat, or air.

This treatment is focused on providing relief from the unpleasant effects of motion on the inner ear and central nervous system. Individuals may take this medication to maintain comfort and function during journeys. The therapeutic domain of Touristil is centered entirely on mitigating these specific travel-related symptoms.

Eligibility Scope

• Populations for whom use is allowed: The medicine is officially approved for use in adults and adolescents who are 12 years of age or older and weigh at least 35 kg.
• Populations for whom use is not recommended: Use is not recommended for women who are breastfeeding due to the potential for excretion of the active substance into human milk. For pregnant women, safety has not been established. Use in older adults (over 60 years) requires special caution due to elevated cardiac risks.
• Populations for whom use is contraindicated: Absolute contraindications apply to individuals with a known hypersensitivity to the active ingredients, moderate or severe hepatic (liver) impairment, or pre-existing cardiac diseases such as congestive heart failure.

Age-related eligibility rules

• The medicine is generally not approved or recommended for children under 12 years of age or those weighing less than 35 kg due to limited safety data and regulatory restrictions.

Condition-specific eligibility rules

• Cardiac and Electrolyte Status: The medicine is strictly contraindicated in patients with known QTc prolongation, significant electrolyte disturbances, or bradycardia.
• Comorbidities: Contraindications extend to patients with a prolactinoma or in cases of gastro-intestinal hemorrhage or mechanical obstruction, as stimulating gut motility would be harmful.
• Interactions: The product is contraindicated if co-administered with certain medications known to prolong the QT interval or potent CYP3A4 inhibitors.

Connection to the overall eligibility profile

Official regulatory documents establish absolute exclusion criteria by defining numerous contraindications tied directly to a patient’s cardiac function, hepatic health, and concurrent medication use. This limits the use of the medicine to populations free of these specific, labeled contraindications.

Interactions with other medicines and products

The official interaction profile for the combination of cinnarizine and dimenhydrinate, the active components in Touristil, documents several clinically relevant pharmaceutical interactions. The product's sedative and anticholinergic effects are a primary domain for interaction, requiring caution or avoidance with concurrent use of other agents.

• Central Nervous System (CNS) Depressants: Co-administration with CNS depressants, including alcohol, barbiturates, narcotic analgesics, and tranquillisers, is associated with a potentiation of the sedative effects of the active components. Patients are officially advised to avoid the consumption of alcoholic beverages.
• Anticholinergic Agents: The concurrent use of other medicines with anticholinergic properties, such as atropine and tricyclic antidepressants, may enhance the anticholinergic effects of the product, leading to increased risk of side effects like dry mouth or urinary retention.
• CYP2D6 Substrates and Inhibitors: Since one active component, dimenhydrinate (metabolised via CYP2D6), is an inhibitor of the CYP2D6 enzyme, co-administration with other drugs that are primarily metabolised by CYP2D6 (e.g., certain beta-blockers, neuroleptics, or selective serotonin reuptake inhibitors) may lead to increased plasma concentrations of these concomitant medications. Caution and monitoring are advised for agents with a narrow therapeutic range.
• QT-Prolonging Medicines: Concomitant administration of medicines that are known to prolong the QT interval on the electrocardiogram, such as Class Ia and Class III anti-arrhythmics, should be avoided due to the potential for increased cardiac risk.
• Specific Drug-Drug Conflicts: The product may oppose the effect of betahistine; therefore, co-administration with betahistine is not recommended in regulatory documents.

Furthermore, the combination may mask the ototoxic symptoms associated with aminoglycosidic antibiotics and may interfere with the results of allergic skin tests.

How Touristil Works

Touristil's mechanism of action involves modulating specific biological pathways, which results in an alteration of receptor activity. The consequence of this mechanism is strictly defined by biochemical interactions and changes in signaling kinetics.

Touristil acts primarily by binding selectively to defined receptor or enzyme targets within the body. This interaction is designed to initiate or suppress specific molecular events, establishing the initial phase of the drug's mechanism. This action is defined by engagement within biological systems characterized by specific receptor- or enzyme-mediated signaling pathways.

Following its initial binding, Touristil operates within larger neural or humoral signaling cascades. The mechanism involves the regulation of signaling by altering the release or reception of key physiological mediators. By influencing the flow of information through these well-characterized molecular sequences, the drug adjusts transmission rates in the targeted pathways.

The resulting change in signaling dynamics within these pathways establishes the foundation for the drug's effect profile.

Touristil, a fixed-dose combination medicine, is administered via the oral route as conventional tablets or orally disintegrating tablets. The medicine is generally taken at the lowest effective dose for the shortest duration necessary, with treatment for acute symptoms typically not exceeding one week.

The standard adult regimen involves dosing the Domperidone component at 10 mg per administration, adhering to a maximum daily oral dose of 30 mg. The administration frequency is generally up to three times daily, with doses requiring appropriate spacing to maintain a minimum interval between administrations.

The timing of administration is a recognized factor: the medicine is typically taken before meals (preferably 15 to 30 minutes prior) as consumption after food may delay absorption. Conventional tablets are swallowed whole with water; they are not intended to be crushed or chewed.

For specific patient populations, such as those with severe renal impairment, there is a reduction in dosing frequency to once or twice daily, depending on the severity of the condition. In the event that a dose is missed and it is close to the next scheduled time, the standard procedure is omitting the missed dose entirely and resuming the regular regimen, which excludes a double dose. This procedural structure defines the short-term usage pattern.

Touristil: Recent Clinical Evidence

The research base for the combination medicine Touristil (Cinnarizine and Domperidone) was studied for its evaluation in conditions related to temporary inner ear disturbances, such as those experienced during motion or travel. The available evidence highlights what is known — and what is still uncertain — about how the fixed-dose combination was evaluated in clinical settings, particularly concerning its immediate effects.

Evidence for Use in Acute Vestibular Symptoms and Motion Sickness

Research explored the product's action in conditions characterized by fluctuating or episodic manifestations linked to the vestibular system, which is responsible for balance. The studies were evaluated in trials assessing short-term or episodic symptom patterns by measuring physiological changes in the inner ear. Short-term Randomized Controlled Trials (RCTs) were conducted during periods of increased symptom activity where subjects underwent controlled stimulation, designed to replicate symptoms of dizziness and motion discomfort. The primary focus of these trials research was applied to outcomes related to systemic or functional imbalance.

The findings describe patterns observed in the studies where the combination product's effect on the inner ear's activity was associated with a measured response shortly after administration. Comparative data indicated patterns where the measured physiological effect was observed sooner than with the single-component agents in the acute phase of administration. These studies help show what has been observed so far in terms of short-term changes to the body's physiological response to motion.

Long-Term Studies and Evidence Gaps

Long-term effects are not fully established regarding the use of the combination product. The pivotal research focused on immediate measurements taken over a few hours post-dose, meaning there is limited information for long-term outcomes such as durability of response or patterns related to repeated, extended use.

The key research was studied for its acute physiological effects mostly in healthy adult volunteers. Consequently, data for certain groups remain insufficient. Subgroup findings are uncertain for older adults (over 60 years of age), who may have different physiological responses. Limited information exists for the pediatric population, and whether an individual with pre-existing comorbidities will respond similarly has not been specifically evaluated in the main trials.

Common questions about Touristil (FAQ)

---

Q: Can Touristil be taken with common over-the-counter pain relievers?

Regulatory documents advise caution regarding co-administration with other medicines, particularly those that are metabolized by the CYP2D6 enzyme or those known to prolong the QT interval (an effect on heart rhythm). While common pain relievers are not explicitly prohibited, official warnings state that the combination medicine's components may interact with drugs in these categories. Regulatory documents describe the importance of reviewing all concomitant medications for potential conflicts.

---

Q: How long does the effect of Touristil usually last?

Regulatory information indicates that the elimination half-life for the Domperidone component of the combination is documented to be around 7.0 to 9.0 hours in humans after oral administration. The half-life describes the time it takes for half of the substance to be eliminated from the body, and this measurement is a factor that influences the described elimination patterns of the medicine.

---

Q: Can Touristil cause rebound symptoms if stopped suddenly?

Regulatory documents contain safety notes that, in some cases related to the Domperidone component, psychiatric withdrawal events have been reported following the sudden discontinuation or dose reduction of the medicine. These reports have primarily occurred when the medicine has been used for extended periods or in higher doses than officially recommended. Official documentation specifies that the medicine should be used according to the prescribed duration.

---

Q: How is the safety of Touristil monitored after it is approved?

Official regulatory bodies mandate ongoing post-marketing surveillance to continuously monitor the safety of the medicine after it is made available to the public. This process requires manufacturers to collect data and submit mandatory reports of all serious adverse drug reactions. This process is designed to ensure the safety profile is continually evaluated throughout the medicine's lifecycle.

---

Q: Does Touristil interact with common vitamins or herbal supplements?

Official product information emphasizes caution when combining this medicine with certain agents that inhibit the CYP3A4 enzyme. While specific vitamins or herbal supplements are not named, regulatory sources generally note that there is limited safety information for combination use with herbal remedies. Information in the official label notes that some supplements may contain ingredients that can affect drug metabolism.

---

Q: Why is the official guidance for use during pregnancy often so cautious?

The cautious guidance provided in regulatory documents is standard practice when the safety of the medicine has not been definitively established for pregnant women. Regulatory bodies require sufficient data to assess the possibility of risk to the developing fetus. When this information is unavailable or limited, the official label includes precautions or explicit warnings regarding use during pregnancy.

All storage and disposal procedures for Touristil (Cinnarizine/Domperidone tablets) must strictly follow the requirements documented in official regulatory labeling to ensure drug quality.

Official Storage and Handling

Item	Regulatory Requirement
Temperature	Store at a temperature not exceeding 25 C or below 30 C. Do not refrigerate or freeze.
Protection	Must be protected from light and moisture. Keep in a cool, dry, and dark place and in the original packaging.
Child Safety	Keep out of the sight and reach of children to prevent accidental ingestion.

Disposal Instructions

Unused or expired tablets should be disposed of according to local regulations. The preferred method is to utilize community drug take-back programs or discard them by mixing with an undesirable substance in a sealed container and placing in the household trash. Do not dispose of the medicine by flushing it down the sink or toilet unless explicitly instructed by the labeling.